HepTcell is a Subunit Vaccine owned by Altimmune, and is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing.
FP-02 is a T-cell vaccine containing Densigens that target different conserved viral or tumour associated proteins such that each Densigen is fused to a fluorocarbon tail. Following T-cell vaccination, patients infected with the corresponding virus or patients harbouring the corresponding tumour, rapidly produce large numbers of both antigen-specific CD4 and CD8 T-cells. CD8 T-cells then kill virus-infected cells or tumour cells directly while CD4 T-cells can, in addition to promoting direct cell killing, recruit other branches of the immune system, including antibodies to attack the target cells.
The revenue for HepTcell is expected to reach a total of $1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the HepTcell NPV Report.
FP-02 (Hepsyn-B, HepTcell) is under development for the treatment of chronic hepatitis-B virus infections. It is administered through intramuscular route. FP-02 is a depovaccine product that contains eight Densigens which are derived from highly conserved regions of the Hepatitis B virus. It is developed based on Densigen platform.
Altimmune, is a a biopharmaceutical company. It focuses on developing liver disease and immune modulating therapies. The company’s pipeline products include ALT-801, a glucagon receptor to treat metabolic dysfunction that leads to non-alcoholic steatohepatitis (NASH). Altimmune also offers nasovax, an intranasally administered recombinant influenza vaccine; and heptcell, an immunotherapy to patients chronically infected with the hepatitis B virus; nasoshield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores. In addition, its products find its application in the treatment of acute respiratory infections, chronic viral infections, and cancer. Altimmune is headquartered in Gaithersburg, Maryland, the US.
The company reported revenues of (US Dollars) US$4.4 million for the fiscal year ended December 2021 (FY2021), a decrease of 46.1% over FY2020. The operating loss of the company was US$96.9 million in FY2021, compared to an operating loss of US$54.8 million in FY2020. The net loss of the company was US$97.1 million in FY2021, compared to a net loss of US$49 million in FY2020.
Quick View – HepTcell
|Highest Development Stage|